{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:07:18Z","timestamp":1792145238884,"version":"4.4.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T00:00:00Z","timestamp":1580688000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CTEP PBTC\u00a0U01"],"award-info":[{"award-number":["CTEP PBTC\u00a0U01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2UM1CA081457"],"award-info":[{"award-number":["2UM1CA081457"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A Pediatric Brain Tumor Consortium (PBTC) phase I\/II trial of veliparib and radiation followed by veliparib and temozolomide (TMZ) was conducted in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). The objectives were to: (i) estimate the recommended phase II dose (RP2D) of veliparib with concurrent radiation; (ii) evaluate the pharmacokinetic parameters of veliparib during radiation; (iii) evaluate feasibility of intrapatient TMZ dose escalation; (iv) describe toxicities of protocol therapy; and (v) estimate the overall survival distribution compared with historical series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Veliparib was given Monday through Friday b.i.d. during radiation followed by a 4-week rest. Patients then received veliparib at 25 mg\/m2 b.i.d. and TMZ 135 mg\/m2 daily for 5 days every 28 days. Intrapatient dose escalation of TMZ was investigated for patients experiencing minimal toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Sixty-six patients (65 eligible) were enrolled. The RP2D of veliparib was 65 mg\/m2 b.i.d. with radiation. Dose-limiting toxicities during radiation with veliparib therapy included: grade 2 intratumoral hemorrhage (n =\u20051), grade 3 maculopapular rash (n =\u20052), and grade 3 nervous system disorder (generalized neurologic deterioration) (n =\u20051). Intrapatient TMZ dose escalation during maintenance was not tolerated. Following a planned interim analysis, it was concluded that this treatment did not show a survival benefit compared with PBTC historical controls, and accrual was stopped for futility. The 1- and 2-year overall survival rates were 37.2% (SE 7%) and 5.3% (SE 3%), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Addition of veliparib to radiation followed by TMZ and veliparib was tolerated but did not improve survival for patients with newly diagnosed DIPG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>NCT01514201<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noaa016","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T15:10:05Z","timestamp":1580483405000},"page":"875-885","source":"Crossref","is-referenced-by-count":95,"title":["A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study"],"prefix":"10.1093","volume":"22","author":[{"given":"Patricia A","family":"Baxter","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack M","family":"Su","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzu","family":"Onar-Thomas","sequence":"first","affiliation":[{"name":"St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A","family":"Billups","sequence":"first","affiliation":[{"name":"St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Nan","family":"Li","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Young","family":"Poussaint","sequence":"first","affiliation":[{"name":"Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward R","family":"Smith","sequence":"first","affiliation":[{"name":"Boston Children\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Thompson","sequence":"first","affiliation":[{"name":"University of North Carolina Children\u2019s Hospital, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekunle","family":"Adesina","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Ansell","sequence":"first","affiliation":[{"name":"AbbVie Laboratories, AbbVie Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Giranda","sequence":"first","affiliation":[{"name":"AbbVie Laboratories, AbbVie Park, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Paulino","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Kilburn","sequence":"first","affiliation":[{"name":"Children\u2019s National Medical Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Quaddoumi","sequence":"first","affiliation":[{"name":"St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Broniscer","sequence":"first","affiliation":[{"name":"St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Blaney","sequence":"first","affiliation":[{"name":"Texas Children\u2019s Hospital\/Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira J","family":"Dunkel","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Fouladi","sequence":"first","affiliation":[{"name":"Cincinnati Children\u2019s Hospital, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,3]]},"reference":[{"issue":"12","key":"2020060921044041800_CIT0001","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/neuonc\/nou103","article-title":"A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report","volume":"16","author":"Su","year":"2014","journal-title":"Neuro Oncol."},{"issue":"1","key":"2020060921044041800_CIT0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ctrv.2011.06.007","article-title":"Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology","volume":"38","author":"Jansen","year":"2012","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"2020060921044041800_CIT0003","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/neuonc\/noq205","article-title":"Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s Oncology Group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro Oncol."},{"issue":"11","key":"2020060921044041800_CIT0004","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/neuonc\/noy070","article-title":"Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma","volume":"20","author":"Gupta","year":"2018","journal-title":"Neuro Oncol."},{"issue":"3","key":"2020060921044041800_CIT0005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat Genet."},{"issue":"6","key":"2020060921044041800_CIT0006","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-015-1478-0","article-title":"Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes","volume":"130","author":"Castel","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2020060921044041800_CIT0007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"issue":"11","key":"2020060921044041800_CIT0008","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/neuonc\/nor115","article-title":"Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target","volume":"13","author":"Smith","year":"2011","journal-title":"Neuro Oncol."},{"issue":"8","key":"2020060921044041800_CIT0009","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2009.25.5463","article-title":"Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets","volume":"28","author":"Zarghooni","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020060921044041800_CIT0010","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1535-7163.MCT-15-0282","article-title":"Poly-ADP-ribose polymerase as a therapeutic target in pediatric diffuse intrinsic pontine glioma and pediatric high-grade astrocytoma","volume":"14","author":"Chornenkyy","year":"2015","journal-title":"Mol Cancer Ther."},{"issue":"12","key":"2020060921044041800_CIT0011","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","article-title":"Poly (ADP-ribose) polymerase inhibitors: recent advances and future development","volume":"33","author":"Scott","year":"2015","journal-title":"J Clin Oncol."},{"issue":"8","key":"2020060921044041800_CIT0012","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"26","key":"2020060921044041800_CIT0013","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1038\/onc.2014.295","article-title":"The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy","volume":"34","author":"Li","year":"2015","journal-title":"Oncogene."},{"issue":"4","key":"2020060921044041800_CIT0014","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"2020060921044041800_CIT0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.semradonc.2010.06.001","article-title":"Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets","volume":"20","author":"Chalmers","year":"2010","journal-title":"Semin Radiat Oncol."},{"issue":"9","key":"2020060921044041800_CIT0016","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2020060921044041800_CIT0017","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/annonc\/mdx505","article-title":"Veliparib with temozolomide or carboplatin\/paclitaxel versus placebo with carboplatin\/paclitaxel in patients with BRCA1\/2 locally recurrent\/metastatic breast cancer: randomized phase II study","volume":"29","author":"Han","year":"2018","journal-title":"Ann Oncol."},{"issue":"10","key":"2020060921044041800_CIT0018","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1158\/1078-0432.CCR-06-2872","article-title":"Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models","volume":"13","author":"Albert","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2020060921044041800_CIT0019","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neo.2015.11.014","article-title":"Evaluation of concurrent radiation, temozolomide and ABT-888 treatment followed by maintenance therapy with temozolomide and ABT-888 in a genetically engineered glioblastoma mouse model","volume":"18","author":"Lemasson","year":"2016","journal-title":"Neoplasia."},{"issue":"3","key":"2020060921044041800_CIT0020","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-009-1044-3","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates","volume":"65","author":"Muscal","year":"2010","journal-title":"Cancer Chemother Pharmacol."},{"issue":"2","key":"2020060921044041800_CIT0021","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-015-1733-1","article-title":"Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase I study","volume":"122","author":"Mehta","year":"2015","journal-title":"J Neurooncol."},{"issue":"6","key":"2020060921044041800_CIT0022","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1191\/1740774505cn121oa","article-title":"Monitoring event times in early phase clinical trials: some practical issues","volume":"2","author":"Thall","year":"2005","journal-title":"Clin Trials."},{"issue":"2","key":"2020060921044041800_CIT0023","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ab.2008.07.007","article-title":"An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors","volume":"381","author":"Liu","year":"2008","journal-title":"Anal Biochem."},{"issue":"4","key":"2020060921044041800_CIT0024","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3171\/2015.12.PEDS15448","article-title":"Using urinary bFGF and TIMP3 levels to predict the presence of juvenile pilocytic astrocytoma and establish a distinct biomarker signature","volume":"18","author":"Pricola Fehnel","year":"2016","journal-title":"J Neurosurg Pediatr."},{"issue":"8","key":"2020060921044041800_CIT0025","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-07-1253","article-title":"Urinary biomarkers predict brain tumor presence and response to therapy","volume":"14","author":"Smith","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2020060921044041800_CIT0026","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40262-013-0130-1","article-title":"Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies","volume":"53","author":"Salem","year":"2014","journal-title":"Clin Pharmacokinet."},{"issue":"6","key":"2020060921044041800_CIT0027","doi-asserted-by":"crossref","first-page":"E1148","DOI":"10.1227\/01.NEU.0000255464.37634.3C","article-title":"A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report","volume":"60","author":"Smith","year":"2007","journal-title":"Neurosurgery."},{"issue":"14","key":"2020060921044041800_CIT0028","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1158\/0008-5472.CAN-13-3116","article-title":"Netrin-1 promotes medulloblastoma cell invasiveness and angiogenesis, and demonstrates elevated expression in tumor tissue and urine of patients with pediatric medulloblastoma","volume":"74","author":"Akino","year":"2014","journal-title":"Cancer Res."},{"issue":"12","key":"2020060921044041800_CIT0029","doi-asserted-by":"crossref","first-page":"984","DOI":"10.18632\/oncotarget.362","article-title":"PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation","volume":"2","author":"van Vuurden","year":"2011","journal-title":"Oncotarget."},{"issue":"1","key":"2020060921044041800_CIT0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12967-017-1164-1","article-title":"Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma","volume":"15","author":"Jue","year":"2017","journal-title":"J Transl Med."},{"issue":"5","key":"2020060921044041800_CIT0031","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv369","article-title":"Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma","volume":"108","author":"Gupta","year":"2016","journal-title":"J Natl Cancer Inst."},{"issue":"10","key":"2020060921044041800_CIT0032","doi-asserted-by":"crossref","first-page":"e26152","DOI":"10.1371\/journal.pone.0026152","article-title":"Modeling pharmacodynamic response to the poly(ADP-ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells","volume":"6","author":"Ji","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"2020060921044041800_CIT0033","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/neuonc\/noq200","article-title":"MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC)","volume":"13","author":"Poussaint","year":"2011","journal-title":"Neuro Oncol."},{"issue":"5","key":"2020060921044041800_CIT0034","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/neuonc\/nov256","article-title":"Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium","volume":"18","author":"Poussaint","year":"2016","journal-title":"Neuro Oncol."},{"issue":"5","key":"2020060921044041800_CIT0035","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00234-014-1348-9","article-title":"\u201cOccult\u201d post-contrast signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis?","volume":"56","author":"Conway","year":"2014","journal-title":"Neuroradiology."},{"issue":"1","key":"2020060921044041800_CIT0036","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3174\/ajnr.A4949","article-title":"Automated processing of dynamic contrast-enhanced MRI: correlation of advanced pharmacokinetic metrics with tumor grade in pediatric brain tumors","volume":"38","author":"Vajapeyam","year":"2017","journal-title":"AJNR Am J Neuroradiol."},{"issue":"8","key":"2020060921044041800_CIT0037","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/neuonc\/nor076","article-title":"Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging","volume":"13","author":"Hipp","year":"2011","journal-title":"Neuro Oncol."},{"issue":"1","key":"2020060921044041800_CIT0038","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat Commun."},{"issue":"1","key":"2020060921044041800_CIT0039","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat Commun."},{"issue":"2","key":"2020060921044041800_CIT0040","doi-asserted-by":"crossref","first-page":"198","DOI":"10.7150\/ijbs.17240","article-title":"Reverse the resistance to PARP inhibitors","volume":"13","author":"Kim","year":"2017","journal-title":"Int J Biol Sci."},{"key":"2020060921044041800_CIT0041","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1748-717X-8-65","article-title":"Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma","volume":"8","author":"Barazzuol","year":"2013","journal-title":"Radiat Oncol."},{"issue":"5","key":"2020060921044041800_CIT0042","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.molonc.2015.12.014","article-title":"Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma","volume":"10","author":"Rasmussen","year":"2016","journal-title":"Mol Oncol."},{"issue":"7","key":"2020060921044041800_CIT0043","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm.2377","article-title":"Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nat Med."},{"issue":"12","key":"2020060921044041800_CIT0044","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2217\/fon-2016-0002","article-title":"Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy","volume":"12","author":"Jenner","year":"2016","journal-title":"Future Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noaa016\/32889776\/noaa016.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/6\/875\/33373541\/noaa016.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/22\/6\/875\/33373541\/noaa016.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T21:05:18Z","timestamp":1591736718000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/22\/6\/875\/5721145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,3]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,2,3]]},"published-print":{"date-parts":[[2020,6,9]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noaa016","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,2,3]]}}}